Antiviral potential of chemokines

BioEssays

Volumn 23, Issue 5, 2001, Pages 428-435

  Mahalingam, Surendran ^a,b   Clark, Kristopher ^a   Matthaei, Klaus I ^a   Foster, Paul S ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b Biology and Environment   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHEMOKINE; CHEMOKINE RECEPTOR;

ANIMAL; BIOLOGICAL MODEL; CYTOTOXICITY; HUMAN; IMMUNOLOGY; LEUKOCYTE; REVIEW; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; CHEMOKINES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LEUKOCYTES; MODELS, BIOLOGICAL; RECEPTORS, CHEMOKINE; VIRUS DISEASES;

EID: 0035024632     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.1061     Document Type: Review

References (73)

1. Mahalingam S, Karupiah G. Chemokines and chemokine receptors in infectious diseases. Immunol Cell Biol 1999;77 469-475.
2. Mahalingam S, Karupiah G. Chemokine modulation by poxvirus infection. Curr Opin Immunol 2000;12:409-412.
3. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Imnunol 2000;18:217-242.
4. Kelner GS, Kennedy J, Bacon KB Kleyensteuber S, Largaespada DA, Jenkins NA, Cope and NG, Bazan JF, Moore KW, Schall TJ, Zlotnik A. Lymphotactin: a cytokine that represents a new class of chemokine. Science 1994;266:1395-1399.
5. Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-568.
6. Ward SG, Bacon K, Westwick J. Chemokines and T lymphocytes: More than an attraction. Immunity 1998;9:1-11.
7. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-314.
8. Clark-Lewis I, Kim KS, Rajarathnam K, Gong JH, Dewald B Moser B, Baggiolini M, Sykes BD. Structure-activity relationships of chemokines. J Leukoc Biol 1995;57:703-711.
9. Gale LM, McColl SR. Chemokines: extracellular messengers for all occasions? Bioessays 1999;21:17-28.
10. Bacon KB, Schall TJ. Chemokines as mediators of allergic inflammation. Int Arch Allergy Immunol 1996;109:97-109.
11. Karpus WJ, Kennedy KJ. MIP-1α and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 1997;62:681-687.
12. Cook DN, Beck MA, Coffman TM, Kirby SL, Sheridan JF, Pragnell IB, Smithies O. Requirement of MIP-1α for an inflammatory response to viral infection. Science 1995;269:1583.
13. Amichay D, Gazzinelli RT, Karupiah G, Moench TR, Sher A, Farber JM. Genes for chemokines MuMig and Crg-2 are induced in protozoan and viral infections in response to IFN-γ with patterns of tissue expression that suggest nonredundant roles in vivo. J Immunol 1996;157:4511-4520.
14. Mahalingam S, Farber JM, Karupiah G. The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity in vivo. J Virol 1999;73:1479-1491.
15. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997;9:551-562.
16. Ramshaw IA, Ramsay AJ, Karupiah G, Roloh MS, Mahalingam S, Ruby JC. Cytokines and immunity to viral infections. Immunol Rev 1997; 159:119-135.
17. Gottlieb SL, Myskowski PL. Int J Dermatol 1994;33:453-461.
18. Krathwohl MD, Hromas R, Brown DR, Broxmeyer HE, Fife KH. Functional characterization of the CC chemokine-like molecules encoded by molluscum contagiosum virus types 1 and 2. Proc Natl Acad Sci USA 1997;94:9875-9880.
19. Senkevich TG, Bugert JJ, Sisler JR, Koonin EV, Darai G, Moss B. Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes. Science 1996;273 813-816.
20. Lalani AS, Graham K, Mossman K, Rajarathnam K, Clark-Lewis I, Kelvin D, McFadden G. The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines. J Virol 1997;71:4356-4363.
21. Lalani AS, McFadden G. Secreted poxvirus chemokine binding proteins. J Leukoc Biol 1997;62:570-576.
22. Alcami A, Symons JA, Colins PD, Williams TJ, Smith GL. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol 1998; 160:624-633.
23. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Alcami A. Vaccinia virus immune evasion. Immunol Rev 1997;159:137-154.
24. Nicholas J, Ruvoio VR, Burns WH, Sandford G, Wan X, Crufo D, Hendrickson SB, Guo HG, Hayward GS, Reitz MS. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med 1997;3287-292.
25. Moore PS, Bosholf C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996;274:1739-1744.
26. Kleda TN, Rosenkilde MM, Coulin F, Simmons G, Johnsen AH, Alouani S, Power CA, Luttichau HR, Gerstoft J, Clapham PR, Clark-Lewis I, Wells TNC, Schwartz TW. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science 1997; 277:1656-1659.
27. Endres MJ, Garlisi CG, Xiao H, Shan L, Hedrick JA. The Kaposi's sarcoma-related herpesvirus (KSHV)-encoded chemokine vMIP-1 is a specific agonist for the CC chemokine receptor (CCR)8. J Exp Med 1999;189:1993-1998.
28. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linkec to cell proliferation. Nature 1997;385:347-350.
29. Geras-Raaka E, Varma A, Ho H, Clark-Lewis I, Gershengom MC. Human interferon-gamma-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. J Exp Med 1998;188:405-408.
30. Melnick JL, Petrie BL, Dreesman GR, Burek J, McCollum CH, DeBakey ME. Cytomegalovirus antigen within human arterial smooth muscle cells Lancet 1983;2:644-647.
31. Peterson PK, Balfour HH, Marker SC, Fryd DS, Howard RJ, Simmons RL. Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors, and impact on renal transplantation. Medicine 1980;59:283-300.
32. Ahuja SK, Gao JL, Murphy PM. Chemokine receptors and molecular mimicry. Immunol Today 1994;15:281-287.
33. Gao JL, Murphy PM. Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor. J Biol Chem 1994;269: 28539-28542.
34. Davis-Poynter NJ, Degli-Esposti M, Farrell HE. Murine cytomegalovirus homologues of cellular immunomodulatory genes. Intervirology 1999;42: 331-341.
35. Neote K, DiGregorio D, Mak JY, Horuk R, Schall TJ. Molecular cloning, functional expression, and signaling characteristics of a CC chemokine receptor. Cell 1993;72:415-425.
36. Vieira J, Schall TJ, Corey L, Geballe AP. Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene. J Virol 1998;72:8158-8165.
37. Bodaghi B, Jones TR, Zipeto D, Vita C, Sun L Laurent L, Arenzana-Seisdedos F, Virelizier JL, Michelson S. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J Exp Med 1998;188:855-866.
38. + T cells. Science 1995;270:1811.
39. Paxton WA, Martin SR, Tse D, O'Brien TR, Skurnick J, VanDevanter NL, Padian N, Braun JF, Kotler DP, Wolinsky SM, Koup RA. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996;2:412-417.
40. Paxton WA, Liu R, Kang S, Wu L, Gingeras TR, Landau NR, Mackay CR, Koup RA. Reduced HIV-1 infectability of CD4+ lymphocytes from exposed-uninfected individuals: association with low expression of CCR5 and high production of bela-chemokines. Virology 1998;244: 66-73.
41. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996;272:1955-1958.
42. Deng H, Liu R, Ellmeier W, Choe S, Ynutmaz D, Burknart M, Di-Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996;381:661-666.
43. Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
44. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane. G protein-coupled receptor Science 1996;272:872-877.
45. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CC-CKR5 structural gene. Science 1996;273:1856-1862.
46. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996;382:722-725.
47. Connor RI, Sheridan KE, Geradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
48. Horuk R, Hesselgesser J, Zhou Y, Faulds D, Halks-Miller M, Harvey S, Taub D, Samson M, Parmentier M, Rucker J, Doranz BJ Doms RW. The CC chemokine 1-309 inhibits CCR8-dependent infection by diverse HIV-1 strains. J Biol Chem 1998;273:386-391.
49. Pal R, Garzino-Demo A, Markham PD, Burns J, Brown M, Gallo RC, DeVico AL. Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 1997;278:695-698.
50. Arenzana-Seisdedos F, Virelizier JL, Rousset D, Clark-Lewis I, Loetscher P, Moser B, Baggiol ni M. HIV blocked by chemokine antagonist. Nature 1996;383:400.
51. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, Buser R, Wells TNC, Proudfoot AE. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997;276:276-279.
52. Hadida F, Vieillard V, Autran B, Clark-Lewis I, Baggiolini M, Debre P. HIV-specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3. J Exp Med 1998;188:609-614.
53. Hadida F, Vieillard V, Mollet L, Clark-Lewis I, Baggiolini M, Debre P. Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells. J Immunol 1999;163:1105-1109.
54. Rouvier E, Luciani MF, Gostein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 1993;177:195-200.
55. Lalani AS, Barrett JW, McFadden G. Modulating chemokines: more lessons from viruses. Immunol Today 2000;21:100-106.
56. Laiani AS, Masters J, Zeng W, Barrett J, Pannu R, Everett H, Arendt CW, McFadden G. Use of chemokine receptors by poxviruses. Science 1999; 286:1968-1971.
57. + T cells. J Immunol 1995;154:5071-5079.
58. + T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547-549.
59. Salazar-Mather TP, Hamilton TA, Biron CA. A chemokine to cytokine to chemokine cascade critical in antivira defence. J Clin Invest 2000;105: 985-993.
60. Martin LB, Kita H, Leiferman KM, Gleich GJ. Eosinophils in allergy role in disease, degranulation, and cytokines. Int Arch Allergy Immunol 1996; 109:207-215.
61. Mould AW, Matthaei KI, Young IG, Foster PS. Relationship between interleukin-5 and eotaxin in regulating blood and tissue eosinophilia in mice. J Clin Invest 1997;99:1064-1071.
62. Rothenberg ME, Zimmermann N, Mishra A, Brandt E, Birkenberger LA, Hogan SP, Foster PS. Chemokines and chemokine receptors: their role in allergic airway disease. J Clin Immunol 1999;19:250-265.
63. Rothenberg ME, MacLean JA, Pearlman E, Luster AD, Leder P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. J Exp Med 1997;135:785-790.
64. Harrison AM, Bonville CA, Rosenberg HF, Domachowske JB. Respiratory syncytical virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am J Respir Crit Care Med 1999;159:1918-1924.
65. Olszewska-Pazdrak B, Casola A, Saito T, Alam R Crowe SE, Mei F, Ogra PL, Garofalo RP. Cell-specific expression of RANTES, MCP-1, and MIP-13 by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus. J Virol 1998;72:4756-4764.
66. Scheerens J, Folkerts G, Van Der Linde H, Sterk PJ, Conroy DM, Williams TJ, Nijkamp FP. Eotaxin levels and eosinophils in guinea pig bronchoalveolar lavage fluid are increased at the onset of a viral respiratory infection. Clin Exp Allergy 1999;29:74-77.
67. Handzel ZT, Busse WW, Sedgwick JB, Vrtis R, Lee WM, Kelly EA, Gern JE. Eosinophils bind rhinovirus and activate virus-specific T cells. J Immunol 1998;160:1279-1284.
68. Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 1998;177: 1458-1464.
69. Domachowske JB, Dyer KD, Adams AG, Leto TL, Rosenberg HF. Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity. Nucleic Acids Res 1998;26:3358-3363.
70. El-Shazly A, Masuyama K, Nakano K, Eura M, Samejima Y, Ishikawa T. Human eotaxin induces eosinophil-derived neurotoxin release from normal human eosinophils. Int Arch Allergy Immunol 1998;117: 55-58.
71. Alam R, Stafford S, Forsythe P, Harrison R, Faubion D, Lett-Brown MA, Grant JA. RANTES is a chemotactic and activating factor for human eosinophils. J Immunol 1993;150:3442-3448.
72. Avila PC, Abisheganaden JA, Wong H, Liu J, Yagi S, Schnurr D, Kishiyama JL, Boushey HA. Effects of allergic inflammation of the nasal mucosa on the severity of rhinovirus 16 cold. J Allergy Clin Immunol 2000;105:923-932.
73. Adamko DJ, Yost BL, Gleich GJ, Fryer AD, Jacoby DB. Ovalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection. Eosinophils mediate airway hyper-responsiveness, m(2) muscarinic receptor dysfunction, and antiviral effects. J Exp Med 1999;190:1465-1478.